RAF1 and lung adenocarcinoma: Given that many lung adenocarcinomas lacking EGFR/RAS/RAF mutations also displayed significant MAPK activation (Cancer Genome Atlas Research, 2014), it is reasonable to predict that there are additional, still undetected MAPK pathway regulators.